首页 > 最新文献

Rational Pharmacotherapy in Cardiology最新文献

英文 中文
Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants 左心室血栓:目前的观点和使用直接口服抗凝剂
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-08 DOI: 10.20996/1819-6446-2022-12-10
A. Aga, A. Sokolova, D. Napalkov
Left ventricular thrombus (LVT) is a serious risk factor for systemic embolism development. Despite the evident danger of this condition, current guidelines describe management of patients with this potentially fatal complication very briefly. LVT can complicate myocardial infarction where its incidence is around 10%, as well as various forms of cardiomyopathies and novel coronavirus infection. According to clinical guidelines vitamin K antagonists (VKAs) should be used as treatment of choice for thrombus resolution. However, experts point out that this therapy lacks necessary evidential base and bears certain difficulties because of pharmacokinetic and pharmacodynamical properties of VKAs. These drawbacks are absent in direct oral anticoagulants (DOACs), the possibility of using which in LVT is being actively studied. As for now, published results of 3 randomised clinical trials have demonstrated similar safety and efficacy profiles of DOACs and VKAs. Similarly, the majority of retrospective cohort studies did not observe significant differences between two groups, where some of them have shown superiority of DOACs especially in terms of earlier thrombus resolution. Nevertheless, some studies have found DOACs ineffective and even potentially unsafe regarding systemic embolism. Existing data does not allow to form an unambiguous conclusion about the equivalence of DOACs and VKAs for LVT resolution. Large randomised clinical trials are needed to determine efficacy and safety of such treatment in these patients.
左心室血栓(LVT)是系统性栓塞发展的严重危险因素。尽管这种情况有明显的危险,但目前的指南非常简单地描述了这种潜在致命并发症的患者管理。LVT可使心肌梗死复杂化,其发病率约为10%,以及各种形式的心肌病和新型冠状病毒感染。根据临床指南,维生素K拮抗剂(VKAs)应作为血栓溶解的治疗选择。然而,专家指出,由于vka的药代动力学和药效学特性,这种治疗方法缺乏必要的证据基础,并且存在一定的困难。这些缺点在直接口服抗凝剂(DOACs)中是不存在的,目前正在积极研究在LVT中使用的可能性。截至目前,已发表的3项随机临床试验结果显示doac和vka的安全性和有效性相似。同样,大多数回顾性队列研究没有观察到两组之间的显著差异,其中一些研究显示了DOACs的优势,特别是在早期血栓溶解方面。然而,一些研究发现DOACs对全身栓塞无效,甚至可能不安全。现有的数据不能对doac和vka在LVT分辨率上的等效性得出明确的结论。需要大型随机临床试验来确定这种治疗在这些患者中的有效性和安全性。
{"title":"Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants","authors":"A. Aga, A. Sokolova, D. Napalkov","doi":"10.20996/1819-6446-2022-12-10","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-10","url":null,"abstract":"Left ventricular thrombus (LVT) is a serious risk factor for systemic embolism development. Despite the evident danger of this condition, current guidelines describe management of patients with this potentially fatal complication very briefly. LVT can complicate myocardial infarction where its incidence is around 10%, as well as various forms of cardiomyopathies and novel coronavirus infection. According to clinical guidelines vitamin K antagonists (VKAs) should be used as treatment of choice for thrombus resolution. However, experts point out that this therapy lacks necessary evidential base and bears certain difficulties because of pharmacokinetic and pharmacodynamical properties of VKAs. These drawbacks are absent in direct oral anticoagulants (DOACs), the possibility of using which in LVT is being actively studied. As for now, published results of 3 randomised clinical trials have demonstrated similar safety and efficacy profiles of DOACs and VKAs. Similarly, the majority of retrospective cohort studies did not observe significant differences between two groups, where some of them have shown superiority of DOACs especially in terms of earlier thrombus resolution. Nevertheless, some studies have found DOACs ineffective and even potentially unsafe regarding systemic embolism. Existing data does not allow to form an unambiguous conclusion about the equivalence of DOACs and VKAs for LVT resolution. Large randomised clinical trials are needed to determine efficacy and safety of such treatment in these patients.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"11 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81157970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of Long-Term Outcomes after Surgical Myocardial Revascularization 心肌血运重建术后远期预后的预测因素
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-08 DOI: 10.20996/1819-6446-2022-12-09
V. Kaveshnikov, M. Kuzmichkina, V. Serebryakova
High mortality from cardiovascular diseases (CVD) requires improved approaches to the treatment of this socially significant pathology. Wide implementation of surgical myocardial revascularization makes it possible to improve significantly both life quality and expectancy in patients with coronary heart disease. The aim of this work was to analyze the literature on the impact of preoperative, operative and postoperative factors on the long-term prognosis after coronary artery bypass grafting (CABG). The review refers to both recent and earlier informative works. The target groups for this article are therapists, cardiologists, rehabilitologists, who work with patients in the short and long term after CABG. Data of Russian and foreign literature show that the long-term prognosis after CABG is largely determined by preoperative factors, in particular – age, set of cardiovascular risk factors (RF) and comorbidity, specifically – severity of coronary and systemic atherosclerosis, incident cardiovascular complications, structural and functional state of the heart. In the aggregate these factors reflect the cumulative effect and further potential of actual cardiovascular RFs, affect longterm risk of adverse events, and determine the therapeutic targets of secondary prevention. Priority of arterial conduits and completeness of revascularization are the main operative factors that determine the course of the long-term period after CABG. Among the postoperative factors, the efficiency of secondary CVD prevention is of paramount importance, in particular – achievement of target RF levels, compensation of cardiac and extracardiac pathology, adherence to the long-term medical therapy, known to improve outcomes based on specific comorbidity. Efficiency of secondary CVD prevention largely depends on patient's health attitudes, the key influence on which beyond attending physician can be provided by participation in rehabilitation programs, teaching patients the meaning and essentials of lifestyle modification and cardiovascular RFs’ control.
心血管疾病(CVD)的高死亡率需要改进治疗这一具有社会意义的病理的方法。外科心肌血运重建术的广泛应用使冠心病患者的生活质量和预期寿命得到显著提高。本研究旨在分析术前、术中及术后因素对冠状动脉旁路移植术(CABG)远期预后影响的文献。这篇评论涉及到最近和早期的信息性作品。本文的目标群体是治疗专家、心脏病专家、康复专家,他们在CABG后与患者进行短期和长期的合作。俄罗斯和国外文献资料显示,CABG术后的长期预后在很大程度上取决于术前因素,特别是年龄、心血管危险因素集(RF)和合并症,特别是冠状动脉和全身动脉粥样硬化的严重程度、心血管并发症的发生率、心脏的结构和功能状态。总的来说,这些因素反映了实际心血管rf的累积效应和进一步潜力,影响不良事件的长期风险,并确定二级预防的治疗目标。动脉导管的优先性和血运重建的完整性是决定冠脉搭桥术后长期病程的主要手术因素。在术后因素中,继发性心血管疾病预防的效率是至关重要的,特别是达到目标射频水平,心脏和心外病理补偿,坚持长期药物治疗,已知可改善基于特定合并症的结果。继发性心血管疾病预防的有效性在很大程度上取决于患者的健康态度,除了主治医生之外,关键的影响因素还包括参与康复计划、教育患者改变生活方式的意义和要点以及心血管RFs的控制。
{"title":"Predictors of Long-Term Outcomes after Surgical Myocardial Revascularization","authors":"V. Kaveshnikov, M. Kuzmichkina, V. Serebryakova","doi":"10.20996/1819-6446-2022-12-09","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-09","url":null,"abstract":"High mortality from cardiovascular diseases (CVD) requires improved approaches to the treatment of this socially significant pathology. Wide implementation of surgical myocardial revascularization makes it possible to improve significantly both life quality and expectancy in patients with coronary heart disease. The aim of this work was to analyze the literature on the impact of preoperative, operative and postoperative factors on the long-term prognosis after coronary artery bypass grafting (CABG). The review refers to both recent and earlier informative works. The target groups for this article are therapists, cardiologists, rehabilitologists, who work with patients in the short and long term after CABG. Data of Russian and foreign literature show that the long-term prognosis after CABG is largely determined by preoperative factors, in particular – age, set of cardiovascular risk factors (RF) and comorbidity, specifically – severity of coronary and systemic atherosclerosis, incident cardiovascular complications, structural and functional state of the heart. In the aggregate these factors reflect the cumulative effect and further potential of actual cardiovascular RFs, affect longterm risk of adverse events, and determine the therapeutic targets of secondary prevention. Priority of arterial conduits and completeness of revascularization are the main operative factors that determine the course of the long-term period after CABG. Among the postoperative factors, the efficiency of secondary CVD prevention is of paramount importance, in particular – achievement of target RF levels, compensation of cardiac and extracardiac pathology, adherence to the long-term medical therapy, known to improve outcomes based on specific comorbidity. Efficiency of secondary CVD prevention largely depends on patient's health attitudes, the key influence on which beyond attending physician can be provided by participation in rehabilitation programs, teaching patients the meaning and essentials of lifestyle modification and cardiovascular RFs’ control.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"56 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83206164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation 血管紧张素受体和奈普利素抑制剂对心力衰竭伴射血分数降低和功能性二尖瓣返流患者生活质量的影响
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-07 DOI: 10.20996/1819-6446-2022-12-05
A. S. Ryazanov, E. Shikh, O. V. Kechina, M. Makarovskaya, A. Kudryavtsev
Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with valsartan in an outpatient practice.Material and Methods. The study included 90 patients with chronic FMR, who were observed for 12 months. They received sacubitril/valsartan or valsartan. Efficiency criteria were: the difference between groups in scores according to the Kansas questionnaire for patients with cardiomyopathy; MR degree parameters (change in effective regurgitation orifice area, vena contracta width, MR volume and MR fraction); indicators of the severity of myocardial remodeling (left ventricular EF; the level of N-terminal brain natriuretic propeptide), exercise tolerance based on a 6-minute walk test, a change in the functional class of heart failure according to NYHA.Results. In a treatment efficacy analysis, the Kansas City Cardiomyopathy Questionnaire–Overall Summary Score improved by 22.1 points in the sacubitril/valsartan group and by 4.5 points in the valsartan group (p<0.001). EF, exercise tolerance, and the number of patients transitioning from NYHA functional class III to II increased in the sacubitril/valsartan group (p<0.05). Also, in this group, the effective area of the regurgitation opening, the width of the vena contracta, the volume of regurgitation, the fraction of regurgitation, and the level of N-terminal brain natriuretic propeptide (p<0.05) decreased more pronouncedly (p<0.05).Conclusion. Compared with valsartan, treatment with sacubitril/valsartan leads to a significant improvement in the quality of life in patients with FMR and HF with reduced EF, which is largely associated with a change in NT-proBNP, echocardiographic characteristics of the severity of MR and the degree of myocardial remodeling.
的目标。比较苏比里尔/缬沙坦与缬沙坦对慢性心力衰竭(CHF)和功能性二尖瓣反流(FMR)患者生活质量指标及主要临床和仪器参数的影响。材料和方法。该研究纳入了90名慢性FMR患者,对他们进行了12个月的观察。他们接受了苏比里尔/缬沙坦或缬沙坦治疗。效率标准为:心肌病患者堪萨斯问卷评分组间差异;MR度参数(有效回流孔面积、静脉收缩宽度、MR体积、MR分数的变化);心肌重构严重程度指标(左室EF;根据nyha的结果,n端脑利钠前肽水平,基于6分钟步行测试的运动耐受性,心力衰竭功能等级的变化。在一项治疗疗效分析中,堪萨斯城心肌病问卷-总体总结评分在苏比里尔/缬沙坦组提高了22.1分,在缬沙坦组提高了4.5分(p<0.001)。舒比利/缬沙坦组EF、运动耐量和NYHA功能从III级过渡到II级的患者数量增加(p<0.05)。反流口有效面积、收缩静脉宽度、反流体积、反流分数、n端脑利钠前肽水平明显降低(p<0.05)。与缬沙坦相比,苏比利/缬沙坦治疗可显著改善FMR和EF降低的HF患者的生活质量,这在很大程度上与NT-proBNP、MR严重程度超声心动图特征和心肌重构程度的改变有关。
{"title":"The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation","authors":"A. S. Ryazanov, E. Shikh, O. V. Kechina, M. Makarovskaya, A. Kudryavtsev","doi":"10.20996/1819-6446-2022-12-05","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-05","url":null,"abstract":"Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with valsartan in an outpatient practice.Material and Methods. The study included 90 patients with chronic FMR, who were observed for 12 months. They received sacubitril/valsartan or valsartan. Efficiency criteria were: the difference between groups in scores according to the Kansas questionnaire for patients with cardiomyopathy; MR degree parameters (change in effective regurgitation orifice area, vena contracta width, MR volume and MR fraction); indicators of the severity of myocardial remodeling (left ventricular EF; the level of N-terminal brain natriuretic propeptide), exercise tolerance based on a 6-minute walk test, a change in the functional class of heart failure according to NYHA.Results. In a treatment efficacy analysis, the Kansas City Cardiomyopathy Questionnaire–Overall Summary Score improved by 22.1 points in the sacubitril/valsartan group and by 4.5 points in the valsartan group (p<0.001). EF, exercise tolerance, and the number of patients transitioning from NYHA functional class III to II increased in the sacubitril/valsartan group (p<0.05). Also, in this group, the effective area of the regurgitation opening, the width of the vena contracta, the volume of regurgitation, the fraction of regurgitation, and the level of N-terminal brain natriuretic propeptide (p<0.05) decreased more pronouncedly (p<0.05).Conclusion. Compared with valsartan, treatment with sacubitril/valsartan leads to a significant improvement in the quality of life in patients with FMR and HF with reduced EF, which is largely associated with a change in NT-proBNP, echocardiographic characteristics of the severity of MR and the degree of myocardial remodeling.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"65 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82620371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to Visits to Medical Institutions and Quality of Therapy after Acute Coronary Syndrome (according to the LIS Registry 3) 急性冠状动脉综合征后坚持到医疗机构就诊和治疗质量(根据LIS注册表3)
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-07 DOI: 10.20996/1819-6446-2022-12-07
N. P. Zolotareva, A. Zagrebelny, M. L. Ginzburg, S. Martsevich, O. Drapkina
Aim. The aim of the research is to evaluate the relationship between patients' adherence to visiting polyclinics after acute coronary syndrome (ACS) and the quality of the therapy they receive.Material and methods. The study was conducted on the basis of the LIS registers (LIS and LIS-3) (Lyubertsy study of mortality) in the Lyubertsy district of the Moscow region. To clarify the vital status of all patients discharged in the first 9 months of 2014 and 2018. from Lyubertsy district hospital 2, contact was established no earlier than 1 year after discharge, and in case of death, its cause was clarified. In the course of a telephone survey, information was obtained on the therapy taken, adherence to visits to medical institutions, a record of cases of cardiovascular events and invasive treatment, hospitalizations due to worsening of the course of the underlying disease for the period after discharge from the hospital was carried out. The search for patients who did not answer the phone call was carried out by studying the archives of polyclinics, using the Megaclinic statistical database, and the data of the individual rehabilitation program for the disabled. In the course of a telephone survey, the response was 60.5%, the search for the remaining patients through statistical databases, the archive of polyclinics made it possible to increase the total response to 87.2%.Results. In the LIS-3 registry, out of 104 patients discharged in 2014, the status was determined in 90 (86.5%) patients, out of 223 patients in 2018 – in 195 (87.4%) patients. During the survey, it was found that 172 patients are observed after discharge from the hospital, 53 patients are not observed at all in the medical facility after discharge. 11 (4.9%) people did not take any groups of medications at the time of the survey. In the group of patients who are highly committed to attending a health facility, the best quality of taking essential medications after discharge from the hospital was noted according to the survey: statins (88.2%, p<0.001), beta-blockers (86.4%, p<0.001) and antiplatelets (90.9%, p=0.001). In both groups, committed and not committed to attending a medical facility, there is a negative dynamics in the quality of taking medications after discharge from the hospital, however, in the group of patients committed to attending a medical facility, it was noted that the odds of taking antiplatelet agents after discharge was 3.4 times higher (OR 3.449, p=0.002), beta-blockers – 4 times (OR 4.103, p<0.001), statins – 4.5 times (OR 4.450, p<0.001), in relation to the group of patients who are not observed in the medical facility after discharge from the hospital.Conclusion. 1-6 years after discharge from the hospital after the reference event, the quality of therapy deteriorated significantly in both groups, mostly in non-adherent patients. Significant differences in the quality of medication intake (antiplatelet agents, statins, β-blockers) were noted in the group o
的目标。本研究的目的是评估急性冠脉综合征(ACS)患者就诊的依从性与他们接受的治疗质量之间的关系。材料和方法。这项研究是在莫斯科地区柳别尔茨县的LIS登记册(LIS和LIS-3)(柳别尔茨死亡率研究)的基础上进行的。明确2014年前9个月和2018年出院患者生命体征状况。在柳别尔茨县第二医院,在出院后不早于1年就与患者建立了联系,在死亡的情况下,对其原因进行了澄清。在电话调查过程中,获得了以下方面的信息:所接受的治疗、是否坚持到医疗机构就诊、心血管事件和侵入性治疗病例的记录、出院后一段时间内因基础疾病病程恶化而住院的情况。对没有接听电话的患者的搜索是通过研究综合诊所的档案,使用Megaclinic统计数据库和残疾人个人康复计划的数据进行的。在电话调查过程中,应答率为60.5%,通过统计数据库搜索剩余患者,通过综合诊所的存档使总应答率提高到87.2%。在LIS-3登记处,2014年出院的104名患者中,有90名(86.5%)患者确定了病情,2018年223名患者中有195名(87.4%)患者确定了病情。在调查中发现,172名患者在出院后接受观察,53名患者在出院后根本没有在医疗机构接受观察。11人(4.9%)在调查时没有服用任何一组药物。根据调查,在高度承诺到医疗机构就诊的患者组中,出院后服用基本药物的质量最高:他汀类药物(88.2%,p<0.001)、β受体阻滞剂(86.4%,p<0.001)和抗血小板药物(90.9%,p=0.001)。在两组中,承诺和未承诺到医疗机构就诊的患者,出院后服用药物的质量呈负动态变化,然而,在承诺到医疗机构就诊的患者组中,值得注意的是,出院后服用抗血小板药物的几率是3.4倍(OR 3.449, p=0.002),受体阻滞剂是4倍(OR 4.103, p<0.001),他汀类药物是4.5倍(OR 4.450, p<0.001)。与出院后未在医疗机构观察的患者组相关。结论。参考事件发生后出院后1-6年,两组治疗质量均显著恶化,主要发生在非依从性患者中。与不去医疗机构的人相比,坚持去医疗机构的人在药物摄入质量(抗血小板药物、他汀类药物、β受体阻滞剂)方面存在显著差异。很明显,出院后对医疗机构的高依从性与更好的药物摄入质量有关。尽管遵守临床建议的质量有所改善,但出院后无论是否前往医疗机构,独立拒绝接受药物治疗的患者比例(4.9%)仍然存在。
{"title":"Adherence to Visits to Medical Institutions and Quality of Therapy after Acute Coronary Syndrome (according to the LIS Registry 3)","authors":"N. P. Zolotareva, A. Zagrebelny, M. L. Ginzburg, S. Martsevich, O. Drapkina","doi":"10.20996/1819-6446-2022-12-07","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-07","url":null,"abstract":"Aim. The aim of the research is to evaluate the relationship between patients' adherence to visiting polyclinics after acute coronary syndrome (ACS) and the quality of the therapy they receive.Material and methods. The study was conducted on the basis of the LIS registers (LIS and LIS-3) (Lyubertsy study of mortality) in the Lyubertsy district of the Moscow region. To clarify the vital status of all patients discharged in the first 9 months of 2014 and 2018. from Lyubertsy district hospital 2, contact was established no earlier than 1 year after discharge, and in case of death, its cause was clarified. In the course of a telephone survey, information was obtained on the therapy taken, adherence to visits to medical institutions, a record of cases of cardiovascular events and invasive treatment, hospitalizations due to worsening of the course of the underlying disease for the period after discharge from the hospital was carried out. The search for patients who did not answer the phone call was carried out by studying the archives of polyclinics, using the Megaclinic statistical database, and the data of the individual rehabilitation program for the disabled. In the course of a telephone survey, the response was 60.5%, the search for the remaining patients through statistical databases, the archive of polyclinics made it possible to increase the total response to 87.2%.Results. In the LIS-3 registry, out of 104 patients discharged in 2014, the status was determined in 90 (86.5%) patients, out of 223 patients in 2018 – in 195 (87.4%) patients. During the survey, it was found that 172 patients are observed after discharge from the hospital, 53 patients are not observed at all in the medical facility after discharge. 11 (4.9%) people did not take any groups of medications at the time of the survey. In the group of patients who are highly committed to attending a health facility, the best quality of taking essential medications after discharge from the hospital was noted according to the survey: statins (88.2%, p&lt;0.001), beta-blockers (86.4%, p&lt;0.001) and antiplatelets (90.9%, p=0.001). In both groups, committed and not committed to attending a medical facility, there is a negative dynamics in the quality of taking medications after discharge from the hospital, however, in the group of patients committed to attending a medical facility, it was noted that the odds of taking antiplatelet agents after discharge was 3.4 times higher (OR 3.449, p=0.002), beta-blockers – 4 times (OR 4.103, p&lt;0.001), statins – 4.5 times (OR 4.450, p&lt;0.001), in relation to the group of patients who are not observed in the medical facility after discharge from the hospital.Conclusion. 1-6 years after discharge from the hospital after the reference event, the quality of therapy deteriorated significantly in both groups, mostly in non-adherent patients. Significant differences in the quality of medication intake (antiplatelet agents, statins, β-blockers) were noted in the group o","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84796079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship of the White Coat Effect with Endpoints and Several Prognostic Indicators in Hypertensive Patients Treated with Regular Antihypertensive Therapy 接受常规降压治疗的高血压患者白大褂效应与终点及若干预后指标的关系
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-07 DOI: 10.20996/1819-6446-2022-12-03
G. F. Andreeva, M. Smirnova, V. Gorbunov, A. Kurekhyan, Y. Koshelyaevskaya
Aim of the study was to evaluate in a prospective cohort study the relationship between the severity of the white coat effect (WHE) in patients with hypertension, who treated with regular antihypertensive therapy, and the composite endpoint, several prognostic indicators, in a routine clinical practice.Material and Methods. We analyzed the data of a prospective cohort study, which included 125 patients with hypertension who received regular antihypertensive therapy. The study consisted of three visits (baseline, 6 and 12 months) and an outcome data collection period (30.1±7.6 months of follow-up after the third visit). This study included three visits every 3 months: 1 visit – screening, ambulatory blood pressure monitoring (ABPM) session, Echo; 2 – assessment of the patient’s status and the therapy effectiveness; 3- assessment of the patient’s status, ABPM session, Echo (the total number of ABPM was 239, Echo - 240). The primary composite endpoint included death for any reason angina pectoris, transient ischemic attack, development of chronic heart failure, arterial revascularization, frequent ventricular extrasystoles, atrial fibrillation, secondary - deterioration of the cardiovascular diseases course and tertiary endpoint – deterioration of the arterial hypertension, concomitant diseases course.Results. The study involved 125 patients: 28 men (22%), 97 women (78%), mean age was 62.6±0.8 years, duration of hypertension 11.6±0.8 years, height 163.6±0.7 cm, body weight 83.1±1.4 kg. The baseline mean daytime systolic BP (SBP) was 125.1±9.8 and diastolic (DBP) – 76.1±7.0 mm Hg, age was 62.8±9.0 years, the WCE level for SBP was 16.5±1.4, for DBP 10.9±0.7 mm Hg. We identified a positive correlation between tertiary composite endpoint data and WCE: for systolic WCE (SWCE) (F = 4.7, p<0.031). We found correlations between WCE and Echo parameters: 1) SWCE level had with LVMI (r = 0.16. p<0.017); 2) diastolic WCE (DWCE) had negative relationship with LV contractility parameters.Conclusions. Thus, only systolic WCE level had correlation with composite endpoint data and LVMI. DWCE level had negative associations with echocardiography LV contractility parameters.
本研究的目的是通过一项前瞻性队列研究,评估在常规临床实践中接受常规降压治疗的高血压患者的白大衣效应(white coat effect, WHE)的严重程度与复合终点(几个预后指标)之间的关系。材料和方法。我们分析了一项前瞻性队列研究的数据,该研究包括125例接受常规降压治疗的高血压患者。该研究包括三次访问(基线,6和12个月)和结果数据收集期(第三次访问后30.1±7.6个月的随访)。本研究包括每3个月3次访问:1次访问-筛查,动态血压监测(ABPM)会话,Echo;2 -评估患者状态及治疗效果;3-评估患者状态、ABPM时段、Echo (ABPM总次数239次,Echo - 240次)。主要综合终点包括任何原因死亡心绞痛、短暂性脑缺血发作、慢性心力衰竭、动脉血运重建术、频繁室性心动过速、心房颤动、心血管疾病病程的二次恶化和第三终点动脉高血压病程的恶化、伴发疾病病程。共纳入125例患者,其中男性28例(22%),女性97例(78%),平均年龄62.6±0.8岁,高血压病程11.6±0.8年,身高163.6±0.7 cm,体重83.1±1.4 kg。基线平均白天收缩压(SBP)为125.1±9.8,舒张压(DBP) - 76.1±7.0 mm Hg,年龄为62.8±9.0岁,收缩压WCE水平为16.5±1.4,舒张压为10.9±0.7 mm Hg。我们发现第三期综合终点数据与WCE呈正相关:收缩压WCE (SWCE) (F = 4.7, p<0.031)。我们发现WCE与Echo参数之间存在相关性:1)SWCE水平与LVMI之间存在相关性(r = 0.16)。p < 0.017);2)舒张期WCE (DWCE)与左室收缩力参数呈负相关。因此,只有收缩期WCE水平与复合终点数据和LVMI相关。DWCE水平与超声心动图左室收缩性参数呈负相关。
{"title":"Relationship of the White Coat Effect with Endpoints and Several Prognostic Indicators in Hypertensive Patients Treated with Regular Antihypertensive Therapy","authors":"G. F. Andreeva, M. Smirnova, V. Gorbunov, A. Kurekhyan, Y. Koshelyaevskaya","doi":"10.20996/1819-6446-2022-12-03","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-03","url":null,"abstract":"Aim of the study was to evaluate in a prospective cohort study the relationship between the severity of the white coat effect (WHE) in patients with hypertension, who treated with regular antihypertensive therapy, and the composite endpoint, several prognostic indicators, in a routine clinical practice.Material and Methods. We analyzed the data of a prospective cohort study, which included 125 patients with hypertension who received regular antihypertensive therapy. The study consisted of three visits (baseline, 6 and 12 months) and an outcome data collection period (30.1±7.6 months of follow-up after the third visit). This study included three visits every 3 months: 1 visit – screening, ambulatory blood pressure monitoring (ABPM) session, Echo; 2 – assessment of the patient’s status and the therapy effectiveness; 3- assessment of the patient’s status, ABPM session, Echo (the total number of ABPM was 239, Echo - 240). The primary composite endpoint included death for any reason angina pectoris, transient ischemic attack, development of chronic heart failure, arterial revascularization, frequent ventricular extrasystoles, atrial fibrillation, secondary - deterioration of the cardiovascular diseases course and tertiary endpoint – deterioration of the arterial hypertension, concomitant diseases course.Results. The study involved 125 patients: 28 men (22%), 97 women (78%), mean age was 62.6±0.8 years, duration of hypertension 11.6±0.8 years, height 163.6±0.7 cm, body weight 83.1±1.4 kg. The baseline mean daytime systolic BP (SBP) was 125.1±9.8 and diastolic (DBP) – 76.1±7.0 mm Hg, age was 62.8±9.0 years, the WCE level for SBP was 16.5±1.4, for DBP 10.9±0.7 mm Hg. We identified a positive correlation between tertiary composite endpoint data and WCE: for systolic WCE (SWCE) (F = 4.7, p<0.031). We found correlations between WCE and Echo parameters: 1) SWCE level had with LVMI (r = 0.16. p<0.017); 2) diastolic WCE (DWCE) had negative relationship with LV contractility parameters.Conclusions. Thus, only systolic WCE level had correlation with composite endpoint data and LVMI. DWCE level had negative associations with echocardiography LV contractility parameters.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"5 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88871489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Healthy Eating in Population Models of Nutrition: Asian Diet Style Summary 人口营养模型中的健康饮食:亚洲饮食风格综述
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-07 DOI: 10.20996/1819-6446-2022-12-08
O. B. Shvabskaia, N. Karamnova, O. Izmailova, O. Drapkina
The population of Japan and Okinawa is known for the longest life expectancy, which many researchers rightly associate with the nature of nutrition existing in these territories. The Japanese diet and Okinawan diet, along with other traditional diets, are real examples of historically established sustainable patterns of healthy eating. Asian eating styles have marked differences from European eating patterns, not only in differences in food sources, but also in eating habits. The article presents the historical, climatic and cultural features of these diets; the issues of food composition, energy and nutritional value of these models of nutrition are considered in detail with an analysis of the differences existing between them; highlights the benefits of products grown mainly in Japan, which are ration-forming for the population of this country; as well as the results of scientific studies on the protective effect of the Japanese and Okinawan diets on human health and disease prevention.
日本和冲绳的人口以预期寿命最长而闻名,许多研究人员正确地将其与这些地区存在的营养性质联系起来。日本饮食和冲绳饮食,以及其他传统饮食,是历史上建立的可持续健康饮食模式的真实例子。亚洲人的饮食方式与欧洲人的饮食方式有明显的不同,不仅在食物来源上有差异,而且在饮食习惯上也有差异。文章介绍了这些饮食的历史、气候和文化特征;详细讨论了这些营养模式的食物成分、能量和营养价值问题,并分析了它们之间存在的差异;强调了主要在日本种植的产品的好处,这些产品正在形成这个国家的人口;以及关于日本和冲绳饮食对人类健康和疾病预防的保护作用的科学研究结果。
{"title":"Healthy Eating in Population Models of Nutrition: Asian Diet Style Summary","authors":"O. B. Shvabskaia, N. Karamnova, O. Izmailova, O. Drapkina","doi":"10.20996/1819-6446-2022-12-08","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-08","url":null,"abstract":"The population of Japan and Okinawa is known for the longest life expectancy, which many researchers rightly associate with the nature of nutrition existing in these territories. The Japanese diet and Okinawan diet, along with other traditional diets, are real examples of historically established sustainable patterns of healthy eating. Asian eating styles have marked differences from European eating patterns, not only in differences in food sources, but also in eating habits. The article presents the historical, climatic and cultural features of these diets; the issues of food composition, energy and nutritional value of these models of nutrition are considered in detail with an analysis of the differences existing between them; highlights the benefits of products grown mainly in Japan, which are ration-forming for the population of this country; as well as the results of scientific studies on the protective effect of the Japanese and Okinawan diets on human health and disease prevention.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"15 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90537605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Acute Coronary Syndrome after Percutaneous Coronary Intervention: State of the Problem and Clinical Practice Data 经皮冠状动脉介入治疗后急性冠状动脉综合征:问题现状及临床实践资料
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-07 DOI: 10.20996/1819-6446-2022-12-04
I. Egorova, N. Vezikova
Aim. To study the prevalence, clinical and endovascular predictors, causes and timing of the development of acute coronary syndrome (ACS) in patients who had previously undergone percutaneous coronary intervention (PCI), as well as the clinical features of the disease and lipid spectrum parameters.Material and methods. The prospective study included 768 patients successively hospitalized from 01.01.2019 to 01.01.2020 in the Regional cardiovascular center, undergoing to emergency coronary angiography.Results. The main group included 768 patients who underwent emergency coronary angiography for ACS. 90 of them had previously undergone PCI (11.7%). Men prevailed (66.7%), the average age was 62 years. 25.5% of patients underwent ACS within a year after coronary stenting, the mean time from PCI to ACS was 43 months. Most often, there was ACS without ST segment elevation (80%). The results of a retrospective analysis of the first PCI showed that 89.7% of patients underwent urgent PCI, 77.8% of patients received bare metal stents. In 67.1% of patients, 1 stent was implanted, the average diameter was 3.2 mm, the average length was 22 mm. Thromboaspiration was performed in 12% of cases, predilatation in 25%, and NC postdilation in 41.3% of cases. Complications of PCI developed in 9% of patients. Stent thrombosis was diagnosed in 7.8% of cases, significant restenosis in 35.6%. Repeated stenting due to ACS was performed in 64.4% of patients, of which 74.6% received 1 stent; average diameter 3.4 mm, average length 24.0 mm. Predilatation was performed in 52.9% of cases, thromboaspiration – in 41.2%, and NC-postdilation – in 86.7% of cases. Complications of PCI developed in 10%. In addition, 99% of patients had significant dyslipidemia. The average cholesterol level was 4.91 mmol/L, the average low-density lipoprotein level was 2.94 mmol/L.Conclusion. Patients after PCI are 12% of group with ACS in clinical practice of the Regional Vascular Center. The most common predictor of recurrent atherothrombotic events is bare metal stent implantation as well as dyslipidemia.
的目标。探讨经皮冠状动脉介入治疗(PCI)患者急性冠脉综合征(ACS)的患病率、临床及血管内预测因素、发病原因及发病时间、疾病临床特征及脂质谱参数。材料和方法。前瞻性研究纳入了768例于2019年1月1日至2020年1月1日在区域心血管中心连续住院,并进行了2次急诊冠状动脉造影的患者。主要组包括768例因急性冠脉综合征接受急诊冠状动脉造影的患者。其中90例既往行PCI(11.7%)。男性占66.7%,平均年龄62岁。25.5%的患者在冠状动脉支架植入术后一年内发生ACS,从PCI到ACS的平均时间为43个月。大多数情况下,ACS没有ST段抬高(80%)。回顾性分析第一次PCI的结果显示,89.7%的患者接受了紧急PCI, 77.8%的患者接受了裸金属支架。67.1%的患者植入1个支架,平均直径3.2 mm,平均长度22 mm。12%的病例进行了血栓抽吸,25%的病例进行了预扩张,41.3%的病例进行了NC后扩张。9%的患者出现PCI并发症。7.8%的病例诊断为支架血栓形成,35.6%的病例诊断为明显的再狭窄。64.4%的患者因ACS进行了重复支架植入,其中74.6%的患者接受了1个支架;平均直径3.4毫米,平均长度24.0毫米。52.9%的病例进行了预扩张,41.2%的病例进行了血栓抽吸,86.7%的病例进行了nc -扩张后。10%出现PCI并发症。此外,99%的患者有明显的血脂异常。平均胆固醇为4.91 mmol/L,平均低密度脂蛋白为2.94 mmol/L。在区域血管中心的临床实践中,行PCI的患者占ACS组的12%。最常见的动脉粥样硬化血栓事件复发的预测因子是裸金属支架植入以及血脂异常。
{"title":"Acute Coronary Syndrome after Percutaneous Coronary Intervention: State of the Problem and Clinical Practice Data","authors":"I. Egorova, N. Vezikova","doi":"10.20996/1819-6446-2022-12-04","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-04","url":null,"abstract":"Aim. To study the prevalence, clinical and endovascular predictors, causes and timing of the development of acute coronary syndrome (ACS) in patients who had previously undergone percutaneous coronary intervention (PCI), as well as the clinical features of the disease and lipid spectrum parameters.Material and methods. The prospective study included 768 patients successively hospitalized from 01.01.2019 to 01.01.2020 in the Regional cardiovascular center, undergoing to emergency coronary angiography.Results. The main group included 768 patients who underwent emergency coronary angiography for ACS. 90 of them had previously undergone PCI (11.7%). Men prevailed (66.7%), the average age was 62 years. 25.5% of patients underwent ACS within a year after coronary stenting, the mean time from PCI to ACS was 43 months. Most often, there was ACS without ST segment elevation (80%). The results of a retrospective analysis of the first PCI showed that 89.7% of patients underwent urgent PCI, 77.8% of patients received bare metal stents. In 67.1% of patients, 1 stent was implanted, the average diameter was 3.2 mm, the average length was 22 mm. Thromboaspiration was performed in 12% of cases, predilatation in 25%, and NC postdilation in 41.3% of cases. Complications of PCI developed in 9% of patients. Stent thrombosis was diagnosed in 7.8% of cases, significant restenosis in 35.6%. Repeated stenting due to ACS was performed in 64.4% of patients, of which 74.6% received 1 stent; average diameter 3.4 mm, average length 24.0 mm. Predilatation was performed in 52.9% of cases, thromboaspiration – in 41.2%, and NC-postdilation – in 86.7% of cases. Complications of PCI developed in 10%. In addition, 99% of patients had significant dyslipidemia. The average cholesterol level was 4.91 mmol/L, the average low-density lipoprotein level was 2.94 mmol/L.Conclusion. Patients after PCI are 12% of group with ACS in clinical practice of the Regional Vascular Center. The most common predictor of recurrent atherothrombotic events is bare metal stent implantation as well as dyslipidemia.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75842262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Efficacy and Tolerability of Antihypertensive Therapy with Single Pill Combinations of Telmisartan in Patients with Arterial Hypertension in Clinical Practice According to the ON TIME Observational Study ON TIME观察研究:替米沙坦单片联合抗高血压在动脉高血压患者中的临床疗效和耐受性
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-07 DOI: 10.20996/1819-6446-2022-12-01
F. Ageev, M. Smirnova
Aim. To assess the clinical outcomes and tolerability of antihypertensive therapy with single pill combinations (SPC) amlodipine + telmisartan and hydrochlorothiazide + telmisartan in clinical practice.Material and methods. Patients with hypertension of grade 1-3 (n=13647; 57.6% women; age 59.3±11.4 years) who received therapy with SPC amlodipine + telmisartan or hydrochlorothiazide + telmisartan were included in an observational multicenter study. Information on complaints, history, previous therapy, history of novel coronavirus infection (COVID-19) during the previous year was obtained. Also, measurement of height, body weight, waist circumference (WC) and hips (HC), office blood pressure (BP) three times with an interval of 4 weeks, completion of questionnaires of satisfaction with therapy using the Likert scale, and assessement of adherence to therapy according to the patient's opinion was performed.Results. A statistically significant decrease in systolic (SBP) and diastolic blood pressure (DBP) was found both in all patients and in the analysis of subgroups according to the grade of hypertension (p<0.001 between visits in all cases). The degree of BP reduction depended on baseline BP levels. The average decrease in SBP/DBP at the 3rd visit for the grade 1 hypertension was 24.5/14.6 mm Hg, for the grade 2 hypertension – 34.4/16.8 mmHg, for the grade 3 hypertension – 49.6/22.1 mmHg (p<0.001 between groups). Target levels of SBP (≤140 mmHg) and DBP (≤90 mmHg) were achieved in 95.3% and 98.1% of patients, respectively. Target levels of SBP (≤130 mmHg) and DBP (≤80 mmHg) were achieved in 74.9% and 78.2% of patients, respectively. WC decreased by 0.5%; HC – by 1.5%; body weight – by 0.42% (p<0.001 in all cases). Scores in patients with a history of COVID-19 did not differ from those in individuals without a history of COVID-19. There were no violations of the therapy regimen during the observation period in 94% of patients. Most doctors and patients were "satisfied" or "completely satisfied" with the clinical effect, convenience and tolerability of therapy. Adverse events occurred in 1.35% of patients.Conclusion. Therapy with SPC amlodipine + telmisartan or hydrochlorothiazide + telmisartan in clinical practice had a high antihypertensive efficacy and had an optimal safety profile. The efficacy of therapy did not depend on the initial grade of hypertension, as well as the past infection with COVID19. The results of the ON TIME study confirm the feasibility of using the SPC amlodipine + telmisartan and hydrochlorothiazide + telmisartan for a wide range of hypertensive patients.
的目标。目的:评价氨氯地平+替米沙坦单片联合(SPC)和氢氯噻嗪+替米沙坦抗高血压的临床疗效和耐受性。材料和方法。1-3级高血压患者(n=13647;57.6%的女性;接受SPC氨氯地平+替米沙坦或氢氯噻嗪+替米沙坦治疗的患者(59.3±11.4岁)纳入观察性多中心研究。收集患者上一年的主诉、病史、既往治疗、新型冠状病毒感染史等信息。测量身高、体重、腰围(WC)、臀围(HC)、办公室血压(BP) 3次,间隔4周,用李克特量表完成治疗满意度问卷,并根据患者意见评估治疗依从性。所有患者的收缩压(SBP)和舒张压(DBP)均有统计学意义的降低,并根据高血压等级进行亚组分析(所有病例就诊间p<0.001)。血压降低的程度取决于基线血压水平。第3次就诊时,1级高血压患者收缩压/舒张压平均下降24.5/14.6 mmHg, 2级高血压患者平均下降34.4/16.8 mmHg, 3级高血压患者平均下降49.6/22.1 mmHg(组间p<0.001)。95.3%和98.1%的患者分别达到收缩压(≤140 mmHg)和舒张压(≤90 mmHg)的目标水平。74.9%和78.2%的患者分别达到收缩压(≤130 mmHg)和舒张压(≤80 mmHg)的目标水平。用水量下降0.5%;HC - 1.5%;体重-减少0.42%(所有病例p<0.001)。有COVID-19病史的患者与没有COVID-19病史的个体的得分没有差异。94%的患者在观察期内未出现违反治疗方案的情况。大多数医患对临床疗效、治疗的便捷性和耐受性“满意”或“完全满意”。不良事件发生率为1.35%。在临床实践中,SPC氨氯地平+替米沙坦或氢氯噻嗪+替米沙坦治疗降压效果高,安全性最佳。治疗的效果并不取决于高血压的初始程度,也不取决于过去是否感染了covid - 19。ON TIME研究的结果证实了SPC氨氯地平+替米沙坦和氢氯噻嗪+替米沙坦治疗大范围高血压患者的可行性。
{"title":"Clinical Efficacy and Tolerability of Antihypertensive Therapy with Single Pill Combinations of Telmisartan in Patients with Arterial Hypertension in Clinical Practice According to the ON TIME Observational Study","authors":"F. Ageev, M. Smirnova","doi":"10.20996/1819-6446-2022-12-01","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-01","url":null,"abstract":"Aim. To assess the clinical outcomes and tolerability of antihypertensive therapy with single pill combinations (SPC) amlodipine + telmisartan and hydrochlorothiazide + telmisartan in clinical practice.Material and methods. Patients with hypertension of grade 1-3 (n=13647; 57.6% women; age 59.3±11.4 years) who received therapy with SPC amlodipine + telmisartan or hydrochlorothiazide + telmisartan were included in an observational multicenter study. Information on complaints, history, previous therapy, history of novel coronavirus infection (COVID-19) during the previous year was obtained. Also, measurement of height, body weight, waist circumference (WC) and hips (HC), office blood pressure (BP) three times with an interval of 4 weeks, completion of questionnaires of satisfaction with therapy using the Likert scale, and assessement of adherence to therapy according to the patient's opinion was performed.Results. A statistically significant decrease in systolic (SBP) and diastolic blood pressure (DBP) was found both in all patients and in the analysis of subgroups according to the grade of hypertension (p<0.001 between visits in all cases). The degree of BP reduction depended on baseline BP levels. The average decrease in SBP/DBP at the 3rd visit for the grade 1 hypertension was 24.5/14.6 mm Hg, for the grade 2 hypertension – 34.4/16.8 mmHg, for the grade 3 hypertension – 49.6/22.1 mmHg (p<0.001 between groups). Target levels of SBP (≤140 mmHg) and DBP (≤90 mmHg) were achieved in 95.3% and 98.1% of patients, respectively. Target levels of SBP (≤130 mmHg) and DBP (≤80 mmHg) were achieved in 74.9% and 78.2% of patients, respectively. WC decreased by 0.5%; HC – by 1.5%; body weight – by 0.42% (p<0.001 in all cases). Scores in patients with a history of COVID-19 did not differ from those in individuals without a history of COVID-19. There were no violations of the therapy regimen during the observation period in 94% of patients. Most doctors and patients were \"satisfied\" or \"completely satisfied\" with the clinical effect, convenience and tolerability of therapy. Adverse events occurred in 1.35% of patients.Conclusion. Therapy with SPC amlodipine + telmisartan or hydrochlorothiazide + telmisartan in clinical practice had a high antihypertensive efficacy and had an optimal safety profile. The efficacy of therapy did not depend on the initial grade of hypertension, as well as the past infection with COVID19. The results of the ON TIME study confirm the feasibility of using the SPC amlodipine + telmisartan and hydrochlorothiazide + telmisartan for a wide range of hypertensive patients.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"33 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77597037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A Case Report of Differential Diagnosis of Causes of Severe Valvular Heart Disease (Takayasu's Arteritis, Infective Endocarditis and Myxomatous Degeneration) with the Key Role of Histological and PCR Examination 重症瓣膜性心脏病(高松动脉炎、感染性心内膜炎和黏液瘤变性)病因鉴别诊断与组织学和PCR检查的关键作用1例
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-07 DOI: 10.20996/1819-6446-2022-12-06
A. Pisaryuk, E. Kotova, P. V. Ageev, A. Moiseeva, N. Povalyaev, E. Domonova, O. Y. Silveistrova, N. S. Tsimbalist, J. I. Babukhina, I. Meray, P. V. Kakhktsyan, A. Meshkov, A. Safarova, Z. Kobalava
Aortic valve lesion is a common and may have diverse causes, from degenerative, congenital and infectious diseases to autoimmune conditions. We present a rare case of Takayasu arteritis and severe heart lesion due to the myxomatous degeneration of the aortic and mitral valves associated with development of infective endocarditis (IE) complicated by abscess, fistula, valve perforation and recurrent acute decompensated heart failure in a young female patient. A combined use of histopathological and PCR analyses of valve tissues was critically important for differential diagnosis of the valve lesions, as it made it possible to identify the true cause of the disease. The presence of Takayasu arteritis has played an indirect role by creating conditions for the development of immunosuppression and determining the disease severity and its progression.
主动脉瓣病变是一种常见的疾病,可能有多种原因,从退行性疾病、先天性疾病和感染性疾病到自身免疫性疾病。我们报告一例罕见的高松动脉炎和严重的心脏病变,由于主动脉瓣和二尖瓣的黏液瘤变性,并发感染性心内膜炎(IE),并发脓肿,瘘,瓣膜穿孔和复发性急性失代偿性心力衰竭的年轻女性患者。瓣膜组织的组织病理学和PCR分析的结合使用对于瓣膜病变的鉴别诊断至关重要,因为它可以确定疾病的真正原因。高须动脉炎的存在通过为免疫抑制的发展创造条件和决定疾病的严重程度及其进展发挥了间接作用。
{"title":"A Case Report of Differential Diagnosis of Causes of Severe Valvular Heart Disease (Takayasu's Arteritis, Infective Endocarditis and Myxomatous Degeneration) with the Key Role of Histological and PCR Examination","authors":"A. Pisaryuk, E. Kotova, P. V. Ageev, A. Moiseeva, N. Povalyaev, E. Domonova, O. Y. Silveistrova, N. S. Tsimbalist, J. I. Babukhina, I. Meray, P. V. Kakhktsyan, A. Meshkov, A. Safarova, Z. Kobalava","doi":"10.20996/1819-6446-2022-12-06","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-06","url":null,"abstract":"Aortic valve lesion is a common and may have diverse causes, from degenerative, congenital and infectious diseases to autoimmune conditions. We present a rare case of Takayasu arteritis and severe heart lesion due to the myxomatous degeneration of the aortic and mitral valves associated with development of infective endocarditis (IE) complicated by abscess, fistula, valve perforation and recurrent acute decompensated heart failure in a young female patient. A combined use of histopathological and PCR analyses of valve tissues was critically important for differential diagnosis of the valve lesions, as it made it possible to identify the true cause of the disease. The presence of Takayasu arteritis has played an indirect role by creating conditions for the development of immunosuppression and determining the disease severity and its progression.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"351 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76575847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natriuresis as a Way to Assess the Effectiveness of Diuretic Therapy for Acute Decompensated Heart Failure: Data from a Pilot Study 钠尿作为一种评估利尿剂治疗急性失代偿性心力衰竭有效性的方法:来自一项初步研究的数据
IF 0.2 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-01-07 DOI: 10.20996/1819-6446-2022-12-13
K. Charaya, D. Shchekochikhin, S. N. Tarasenko, N. Ananicheva, S. A. Sovetova, T. V. Soboleva, O. Dikur, A. Borenstein, D. Andreev
Aim. To analyze the clinical significance of the sodium level in a single urine test obtained 2 hours after the first dose of a loop diuretic was administered in patients with acute decompensation of chronic heart failure (ADHF).Material and methods. An observational study was conducted on the basis of a rapid-care hospital. The concentration of sodium in urine analysis obtained 2 hours after intravenous administration of the first dose of loop diuretic and natriuresis for the first day of hospitalization were evaluated. The development of resistance to diuretics was taken as the primary endpoint (the need to increase the daily dose of furosemide by more than 2 times compared to the initial one or the addition of another class of diuretic drugs).Results. 25 patients with ADHF were included. The average age of patients was 69.0±14.8 years, 16 (64%) of them were men. The average left ventricular ejection fraction was 49.0±13.5%. The level of the N‐terminal fragment of the brain natriuretic peptide (NT-proBNP) was 3416 (2128; 5781) pg/ml. The average sodium concentration in the urine analysis obtained 2 hours after the start of treatment was 100.6±41.0 mmol / l. The concentration of sodium in urine for the first day was 102.2±39.0 mmol/l. 2 hours after the start of treatment, the sodium concentration in a single urine test was less than 50 mmol/l in 5 (20%) patients. Upon further observation, oligoanuria (defined as diuresis of less than 400 ml within 24 hours) developed in 2 of them. Oligoanuria was not detected among patients whose sodium concentration was more than 50 mmol/l. The need for escalation (any increase in the dose of a loop diuretic and/or the addition of another class of diuretic drugs) arose in 7 (28%) patients; at the same time, we diagnosed the development of resistance to diuretics in 5 (20%) of them. Resistance to diuretics was more common among patients with a sodium concentration in a single urine test obtained 2 hours after the start of furosemide administration, less than 50 mmol/l (p=0.037); when dividing the recruited patient population into subgroups with a sodium concentration in a single urine test ≥50 mmol/l and <50 mmol/l there was no significant difference in the need for any escalation of diuretic therapy [3 (60%) vs 4 (20%), p=0.07].Conclusion. Resistance to diuretics is more common among patients with a sodium concentration in a single urine test obtained 2 hours after the first dose of furosemide, less than 50 mmol / l. Evaluation of natriuresis allows to identify insufficient effectiveness of diuretic therapy already at the beginning of treatment.
的目标。目的分析慢性心力衰竭急性失代偿(ADHF)患者首次使用利尿剂2小时后单次尿钠水平的临床意义。材料和方法。一项观察性研究是在一家快速护理医院进行的。静脉给予第一剂利尿剂2小时后的尿钠浓度分析和住院第一天的尿钠分析。以对利尿剂的耐药性为主要终点(与初始剂量相比,需要将速尿的日剂量增加2倍以上或添加另一类利尿剂)。纳入ADHF患者25例。患者平均年龄69.0±14.8岁,男性16例(64%)。平均左室射血分数为49.0±13.5%。脑利钠肽N端片段(NT-proBNP)的水平为3416 (2128;5781) pg / ml。治疗开始后2 h尿钠平均浓度为100.6±41.0 mmol/l,第1天尿钠平均浓度为102.2±39.0 mmol/l。治疗开始2小时后,5例(20%)患者单次尿钠浓度低于50 mmol/l。进一步观察,其中2例出现少尿(定义为24小时内利尿量小于400ml)。钠浓度大于50 mmol/l的患者无少尿。7例(28%)患者需要增加剂量(增加环形利尿剂剂量和/或添加另一类利尿剂);同时,我们诊断出其中5例(20%)出现利尿剂耐药性。利尿剂耐药在开始给药后2小时单次尿钠浓度低于50 mmol/l的患者中更为常见(p=0.037);当将招募的患者人群按单次尿钠浓度≥50 mmol/l和<50 mmol/l分为亚组时,利尿剂治疗升级的需求无显著差异[3 (60%)vs 4 (20%), p=0.07]。利尿剂耐药在首次给药后2小时单次尿钠浓度低于50 mmol / l的患者中更为常见。对尿钠的评估可以在治疗开始时确定利尿剂治疗的有效性不足。
{"title":"Natriuresis as a Way to Assess the Effectiveness of Diuretic Therapy for Acute Decompensated Heart Failure: Data from a Pilot Study","authors":"K. Charaya, D. Shchekochikhin, S. N. Tarasenko, N. Ananicheva, S. A. Sovetova, T. V. Soboleva, O. Dikur, A. Borenstein, D. Andreev","doi":"10.20996/1819-6446-2022-12-13","DOIUrl":"https://doi.org/10.20996/1819-6446-2022-12-13","url":null,"abstract":"Aim. To analyze the clinical significance of the sodium level in a single urine test obtained 2 hours after the first dose of a loop diuretic was administered in patients with acute decompensation of chronic heart failure (ADHF).Material and methods. An observational study was conducted on the basis of a rapid-care hospital. The concentration of sodium in urine analysis obtained 2 hours after intravenous administration of the first dose of loop diuretic and natriuresis for the first day of hospitalization were evaluated. The development of resistance to diuretics was taken as the primary endpoint (the need to increase the daily dose of furosemide by more than 2 times compared to the initial one or the addition of another class of diuretic drugs).Results. 25 patients with ADHF were included. The average age of patients was 69.0±14.8 years, 16 (64%) of them were men. The average left ventricular ejection fraction was 49.0±13.5%. The level of the N‐terminal fragment of the brain natriuretic peptide (NT-proBNP) was 3416 (2128; 5781) pg/ml. The average sodium concentration in the urine analysis obtained 2 hours after the start of treatment was 100.6±41.0 mmol / l. The concentration of sodium in urine for the first day was 102.2±39.0 mmol/l. 2 hours after the start of treatment, the sodium concentration in a single urine test was less than 50 mmol/l in 5 (20%) patients. Upon further observation, oligoanuria (defined as diuresis of less than 400 ml within 24 hours) developed in 2 of them. Oligoanuria was not detected among patients whose sodium concentration was more than 50 mmol/l. The need for escalation (any increase in the dose of a loop diuretic and/or the addition of another class of diuretic drugs) arose in 7 (28%) patients; at the same time, we diagnosed the development of resistance to diuretics in 5 (20%) of them. Resistance to diuretics was more common among patients with a sodium concentration in a single urine test obtained 2 hours after the start of furosemide administration, less than 50 mmol/l (p=0.037); when dividing the recruited patient population into subgroups with a sodium concentration in a single urine test ≥50 mmol/l and <50 mmol/l there was no significant difference in the need for any escalation of diuretic therapy [3 (60%) vs 4 (20%), p=0.07].Conclusion. Resistance to diuretics is more common among patients with a sodium concentration in a single urine test obtained 2 hours after the first dose of furosemide, less than 50 mmol / l. Evaluation of natriuresis allows to identify insufficient effectiveness of diuretic therapy already at the beginning of treatment.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"17 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73352784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Rational Pharmacotherapy in Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1